Diabetes and ischemic heart disease: The specific therapy;Diabete e cardiopatia ischemica: la terapia specifica

Giornale Italiano di Cardiologia

Volumn 9, Issue 10 SUPPL.1, 2008, Pages

  Raddino, Riccardo ^a   Bonadei, Ivano ^a   Teli, Melissa ^a   Robba, Debora ^a   Caretta, Giorgio ^a   Madureri, Alberto ^a   Zanini, Gregoriana ^a   Pedrinazzi, Claudio ^b   Vizzardi, Enrico ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b OSPEDALE MAGGIORE   (Italy)

Author keywords

ACE inhibitors; Beta adrenergic blockers; Coronary artery bypass grafting; Diabetes mellitus; Ischemic heart disease; Thrombolytic therapy

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE CORONARY SYNDROME; ARTICLE; DIABETIC ANGIOPATHY; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN;

ACUTE CORONARY SYNDROME; ADRENERGIC ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY;

EID: 59849127766     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002; 106: 1783-7.
2. Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853-63.
3. Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102: 2180-4.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
5. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 2002; 90: 625-8.
6. Mehta SR, Yusuf S, Peters RJ, et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
7. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.
8. Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation 2002; 106: 394-8.
9. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-45.
10. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-84.
11. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
12. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML, for the EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369-78.
13. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
14. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The CARE Investigators. Circulation 1998; 98: 2513-9.
15. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661-7.
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R, for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo- controlled trial. Lancet 2003; 361: 2005-16.
17. Colhoun HM, Betteridge DJ, Durrington PN, et al, for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
18. The BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35: 1122-9.
19. Niles NW, McGrath PD, Malenka D, et al, for the Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. J Am Coll Cardiol 2001; 37: 1008-15.
20. Scheen AJ, Warzee F, Legrand VM. Drug-eluting stents: a meta-analysis in diabetic patients. Eur Heart J 2004; 25: 2167-8.
21. Sedlis SP, Morrison DA, Lorin JD, et al, for the Investigators of the Dept of Veterans Affairs Cooperative Study 385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 2002; 40: 1555-66.
22. Lorusso R, Pentiricci S, Raddino R, et al. Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. Diabetes 2003; 52: 2814-20.